| 前收市價 | 58.50 |
| 開市 | 59.62 |
| 買盤 | 59.55 x 800 |
| 賣出價 | 59.81 x 100 |
| 今日波幅 | 58.58 - 61.37 |
| 52 週波幅 | 25.98 - 110.25 |
| 成交量 | |
| 平均成交量 | 2,063,736 |
| 市值 | 6.995B |
| Beta 值 (5 年，每月) | 0.75 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -5.40 |
| 業績公佈日 | 2024年8月08日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 82.35 |
ZacksCytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investor's Business DailyCytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street
Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed.
InvestorPlace7 Biotech Stocks to Boost Your Portfolio to Peak Health
While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks. First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressin
